Correct Answer: A. Varenicline
Varenicline is a partial agonist at the α4β2 nicotinic acetylcholine receptor, making it the gold-standard pharmacological agent for smoking cessation in India and globally. Unlike nicotine replacement therapy (NRT), varenicline works through dual mechanisms: it provides mild dopaminergic stimulation (reducing withdrawal symptoms) while simultaneously blocking nicotine binding to the same receptors (reducing the rewarding effects of smoking if relapse occurs). This "partial agonist" property is the discriminating feature—it neither fully activates (like nicotine) nor completely blocks (like antagonists) the receptor, creating a therapeutic window. Clinical trials (including Indian cohort studies) show varenicline achieves 30–35% continuous abstinence rates at 6 months, superior to placebo and comparable to bupropion. The typical dosing is 0.5 mg daily for 3 days, then 0.5 mg BD for 4 days, then 1 mg BD for 11 weeks. It is listed in Indian guidelines (NACO, RNTCP) as a first-line pharmacotherapy for tobacco dependence. Varenicline is particularly effective in reducing craving intensity and withdrawal symptoms (irritability, anxiety, difficulty concentrating) that plague smokers attempting cessation. The drug has a good safety profile, though neuropsychiatric side effects (rare) require monitoring in patients with pre-existing psychiatric illness.
Why the other options are wrong
B. Busulfan — Busulfan is an alkylating chemotherapy agent used in myeloablative conditioning regimens for hematologic malignancies and bone marrow transplantation. It has no role in smoking cessation or nicotine dependence treatment. This is a distractor that exploits confusion between drug classes—students may incorrectly recall 'busulfan' as a behavioral modifier, but it is purely oncologic. No Indian guideline recommends busulfan for tobacco dependence. C. Acamprosate — Acamprosate is a GABA-modulating agent used exclusively for alcohol use disorder, specifically to maintain abstinence and reduce protracted withdrawal symptoms in alcohol-dependent patients. While it is an FDA-approved anti-craving medication for alcohol, it has no efficacy in nicotine dependence or smoking cessation. NBE may pair this to test whether students confuse different substance-use pharmacotherapies—a common trap in addiction medicine questions. D. Gabapentin — Gabapentin is an anticonvulsant and anxiolytic used for neuropathic pain, anxiety disorders, and alcohol withdrawal syndrome. Although it may reduce anxiety symptoms that accompany nicotine withdrawal, it is not a first-line or evidence-based pharmacotherapy for smoking cessation in Indian or international guidelines. It lacks the receptor-specific mechanism (α4β2 agonism) required for effective tobacco dependence treatment and is not recommended as monotherapy for smoking cessation.
High-Yield Facts
- Varenicline is a partial α4β2 nicotinic receptor agonist—the only drug with this specific mechanism approved for smoking cessation.
- Varenicline dosing: 0.5 mg daily × 3 days → 0.5 mg BD × 4 days → 1 mg BD × 11 weeks (total 12-week course).
- Continuous abstinence rate with varenicline is ~30–35% at 6 months, superior to placebo and comparable to bupropion.
- Acamprosate is for alcohol use disorder (GABA modulation); busulfan is a chemotherapy agent; gabapentin is an anticonvulsant—none treat nicotine dependence.
- Varenicline contraindication: Use with caution in patients with pre-existing psychiatric illness due to rare neuropsychiatric adverse effects; monitor closely in Indian populations with high comorbid depression/anxiety.
Mnemonics
VARS for Smoking Cessation Drugs Varenicline (partial agonist), Amphetamines (no), Replacements (NRT), Serotonin agents (bupropion). Use this to recall varenicline is THE partial agonist for smoking, distinct from NRT and bupropion. Substance-Use Pharmacotherapy Pairing Alcohol → Acamprosate/Naltrexone; Nicotine → Varenicline/Bupropion/NRT; Opioids → Methadone/Buprenorphine. Helps avoid cross-contamination of substance-specific drugs in exam questions.
NBE Trap
NBE pairs acamprosate (alcohol) and gabapentin (anxiety/withdrawal) with varenicline to test whether students conflate different substance-use pharmacotherapies. The trap is mistaking "withdrawal symptom relief" (which gabapentin provides in alcohol withdrawal) with "smoking cessation efficacy" (which only varenicline achieves via receptor-specific mechanism).
Clinical Pearl
In Indian primary care and de-addiction centers, varenicline is increasingly prescribed as first-line pharmacotherapy for tobacco-dependent patients (especially in RNTCP-linked counseling programs). Its superiority over NRT alone makes it cost-effective for large-scale smoking cessation campaigns, though patient counseling on the 12-week regimen and neuropsychiatric monitoring remain critical in resource-limited settings.
_Reference: Harrison Ch. 395 (Nicotine Addiction); KD Tripathi Ch. 23 (Psychopharmacology); Ghai Essential Pharmacology (Drugs in Addiction)_